A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 1, 2008, Pages 109-115

  LoConte, Noelle K ^a   Thomas, James P ^b   Alberti, Dona ^a   Heideman, Jennifer ^a   Binger, Kimberly ^a   Marnocha, Rebecca ^a   Utecht, Kyle ^c   Geiger, Peter ^a   Eickhoff, Jens ^a   Wilding, George ^a   Kolesar, Jill ^a,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Bortezomib; Doxorubicin; Proteasome inhibition; Ubiquitination

Indexed keywords

BORTEZOMIB; DOXORUBICIN; PROTEASOME; PROTEIN; UBIQUITIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; UBIQUITINATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZINES; SALVAGE THERAPY; TREATMENT OUTCOME; UBIQUITINATION;

EID: 53149091626     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0719-5     Document Type: Article

References (25)

1. C Aghajanian S Soignet DS Dizon 2002 A phase 1 trial of the novel proteosome inhibitor PS314 in advanced solid tumor malignancies Clin Cancer Res 8 2505 11
2. J Adams 2002 Preclinical and clinical evaluation of proteasome inhibitor bortezomib for the treatment of cancer Curr Opin Chem Biol 6 493 500
3. J An Y Sun M Fisher 2004 Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas Leukemia 18 1699 704
4. A Devoy T Soane R Welchman 2005 The ubiquitin-proteasome system and cancer Essays Biochem 41 187 203
5. WD DeWys M Bauer J Colsky 1977 Comparitive trial of adriamycin and 5-fluorouracil in advanced prostatic cancer-progress report, Cancer Treat Rep 61 325 328
6. SC Dhananjayan A Ismail Z Nawaz 2005 Ubiquitin and control of transcription Essays Biochem 41 69 80
7. GK Dy JP Thomas G Wilding 2005 A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer Clin Cancer Res 11 9 3410 6
8. MR Fekete WH McBride F Pajonk 2005 Anthracyclines, proteasome activity and multi-drug-resistance BMJ Cancer 5 114
9. RI Fisher SH Bernstein BS Kahl 2006 Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma Jl Clin Oncol 24 30 4867 4874
10. PH Gumerlock T Kawaguchi LP Moisan 2002 Mechanisms of enhanced cytotoxicity from docetaxel-PS-341 combination in non-small cell lung carcinoma (NSCLC) Proc Am Soc Clin Oncol 21 304a (abstract 1214)
11. NB Hass J Manola G Hudes 2000 Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer Am J Clin Oncol 23 589 592
12. T Hideshima P Richardson D Chauhan 2001 The proteasome inhibitor bortezomib inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 3071 3076
13. S Jagannath B Barlogie J Berenson 2004 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 2 165 172
14. J Kiyomiya H Hiroshi K Masaru 2002 Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteasome Int J of Oncol 21 1081 1085
15. MN Ma HH Yang K Parker 2003 The proteasome inhibitor bortezomib markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents Clin Cancer Res 9 1136 1144
16. N Mitsiades CS Mitsiades PG Richardson 2003 The proteasome inhibitor bortezomib potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood 101 2377 2380
17. D Nandi P Tahiliani A Kumar 2006 The ubiquitin-proteasome system J Biosci 31 1 137 155
18. CN Papandreou DD Daliani D Nix 2004 Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J Clin Oncol 22 11 2108 2121
19. ME Pereira B Yu S Wilk 1992 Enzymatic changes of the bovine pituitary multicatalytic proteinase complex induced by magnesium ions Arch Biochem Biophys 294 1 8
20. PG Richardson B Barlogie J Berenson 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2609 2617
21. PG Richardson B Barlogie J Berenson 2004 Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory myeloma: an update of the SUMMIT trial with additional follow-up Hematol Jl 5 Suppl 2 S103 S104
22. P Richardson P Sonneveld MW Schuster 2005 Bortezomib or high dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 24 2487 2498
23. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Canc Inst 92 205 216
24. FM Torti D Aston BL Lum 1983 Weekly doxorubicin in endocrine-refractory carcinoma of the prostate J Clin Oncol 1 477 482
25. Q Xu M Farah JM Webster RJ Wojcikiewicz 2004 Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor Mol Cancer Ther 3 10 1263 9